These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. HE4 in ovarian cancer: from discovery to clinical application. Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, Lippi G. Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021 [Abstract] [Full Text] [Related]
8. Current clinical use of biomarkers for epithelial ovarian cancer. Moore RG, Maclaughlan S. Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519 [Abstract] [Full Text] [Related]
15. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, Høgdall C. Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323 [Abstract] [Full Text] [Related]
16. Multiple biomarker panels for early detection of ovarian cancer. Yurkovetsky ZR, Linkov FY, E Malehorn D, Lokshin AE. Future Oncol; 2006 Dec; 2(6):733-41. PubMed ID: 17155900 [Abstract] [Full Text] [Related]
17. [Biomarker in gynecologic malignancies]. Isonishi S. Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576 [Abstract] [Full Text] [Related]
18. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Kim YW, Bae SM, Kim IW, Liu HB, Bang HJ, Chaturvedi PK, Battogtokh G, Lim H, Ahn WS. Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176 [Abstract] [Full Text] [Related]